Gilead Sciences Inc
NASDAQ: GILD
$91.00
+$1.06 (+1.2%)
Closing Price on January 14, 2025
GILD Articles
24/7 Wall St. has identified five of the lowest performing health care stocks over the past month which need to catch up to peers.
Published:
With the markets at or near record highs, the volume of insider selling has reached some of the highest levels this year.
Published:
A new research report from the analysts at UBS focuses on four companies that stand to benefit from rising demand for the drugs they produce that treat hepatitis C.
Published:
A Gilead Sciences bond offering and a key insider stock sale netting over $14 million should be considered by investors.
Published:
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies, such as Ebola-vaccine companies.
Published:
A new research note from Cowen focuses on health care companies that have released earnings and offer investors reasons to own the stocks.
Published:
Gilead Sciences reported disappointing third-quarter results after the market close on Monday.
Published:
Gilead Sciences is set to report its third-quarter earnings after the U.S. markets close on Tuesday.
Published:
Short interest in biotech leaders changed from directional to stock specific in the first two weeks of October.
Published:
Rising trends in prescriptions and higher, yet beatable increases in earnings have set the table for what the UBS biotech analysts feels could be a very solid third-quarter earnings season.
Published:
In a new research report, Deutsche Bank analysts suggest investors focus on sectors like technology, health care, financials and selected industrials.
Published:
A new research report from Merrill Lynch highlights 10 top catalyst-driven ideas for the fourth quarter.
Published:
Short sellers are often active in biotech stocks, and we have seen some excessive short interest activity in the most recent report.
Published:
A new research report from UBS focuses on four top companies that are making great strides in treatments for patients -- and generating gigantic revenues.
Published:
Short sellers are often active in biotech stocks, and we have seen some excessive short interest activity in the latest report.
Published:
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.